AstraZeneca Development Pipeline
28 January 2010
Line Extensions
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Cardiovascular |
|||||
Crestor |
statin |
outcomes in subjects with elevated CRP |
III |
Filed |
Filed |
Onglyza/ metformin FDC# |
DPP-4 inhibitor + biguanide FDC |
diabetes |
III |
3Q 2010 |
Filed |
Dapagliflozin/ metformin FDC# |
SGLT2 inhibitor + biguanide FDC |
diabetes |
III |
2H 2011 |
2H 2011 |
Gastrointestinal |
|||||
Nexium |
proton pump inhibitor |
peptic ulcer bleeding |
III |
Launched |
Filed |
Axanum |
proton pump inhibitor + low dose aspirin FDC |
low dose aspirin associated peptic ulcer |
III |
3Q 2010* |
Filed |
Neuroscience |
|||||
Seroquel |
D2/5HT2 antagonist |
bipolar maintenance |
III |
Launched |
Launched |
Seroquel XR |
D2/5HT2 antagonist |
major depressive disorder |
III |
Filed |
Approved |
Seroquel XR |
D2/5HT2 antagonist |
generalised anxiety disorder |
III |
Filed |
Filed |
Oncology & Infection |
|||||
FluMist |
live, attenuated, intranasal influenza virus vaccine |
influenza |
III |
Filed |
Launched |
Iressa |
EGFR tyrosine kinase inhibitor |
NSCLC |
III |
Launched |
TBD |
Faslodex |
oestrogen receptor antagonist |
first line advanced breast cancer |
III |
|
|
Faslodex |
oestrogen receptor antagonist |
high dose (500mg) second line advanced breast cancer |
III |
Filed |
Filed |
Motavizumab# |
humanized MAb binding to RSV F protein |
early and late treatment of RSV in paeds >1 yr |
II |
|
2015 |
MEDI-3414 |
H1N1 influenza |
pandemic flu prevention |
III |
|
Launched |
#Partnered product
*Previously submission was indication only. Now covers fixed dose combination
NCEs
Phase III/Registration
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Cardiovascular |
|||||
Onglyza# |
DPP-4 inhibitor |
diabetes |
III |
Launched |
Launched |
Brilinta/Brilique |
ADP receptor antagonist |
arterial thrombosis |
III |
Filed |
Filed |
Certriad# |
statin + fibrate fixed combination |
dyslipidaemia |
III |
|
Filed |
Dapagliflozin# |
SGLT2 inhibitor |
diabetes |
III |
4Q 2010 |
4Q 2010* |
Neuroscience |
|||||
Vimovo# |
naproxen + esomeprazole |
signs and symptoms of OA, RA and AS |
III |
Filed |
Filed |
Oncology & Infection |
|||||
Motavizumab# |
humanized MAb binding to RSV F protein |
RSV prevention |
III |
4Q 2010 |
Filed |
Zactima |
VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity |
medullary thyroid cancer - orphan |
III |
3Q 2010 |
3Q 2010 |
Recentin |
VEGFR tyrosine kinase inhibitor |
CRC |
III |
4Q 2010 |
4Q 2010 |
Recentin |
VEGFR tyrosine kinase inhibitor |
recurrent glioblastoma - orphan |
III |
4Q 2010 |
4Q 2010 |
Zibotentan (ZD4054) |
endothelin A receptor antagonist |
castrate resistant prostate cancer |
III |
1H 2011 |
1H 2011 |
Ceftaroline# |
affinity to penicillin- binding proteins |
pneumonia /skin infections |
III |
3Q 2010 |
NA |
#Partnered product
*Timing subject to CV event rate
NCEs
Phases I and II
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Cardiovascular |
|||||
AZD0837 |
direct thrombin inhibitor |
thrombosis |
II |
|
|
AZD6370 |
GK activator |
diabetes |
II |
|
|
AZD1656 |
GK activator |
diabetes |
II |
2015 |
2015 |
AZD6482 |
PI3K-beta inhibitor |
thrombosis |
I |
|
|
AZD4017 |
11BHSD inhibitor |
diabetes/obesity |
I |
|
|
AZD6714 |
GK activator |
diabetes |
I |
|
|
AZD8329 |
11BHSD inhibitor |
diabetes/obesity |
I |
|
|
AZD7687 |
diacylglycerol acyl transferase -1 inhibitor |
diabetes/obesity |
I |
|
|
Gastrointestinal |
|||||
Lesogaberan (AZD3355) |
GABAB agonist |
GERD |
II |
2013 |
2013 |
AZD1386 |
vanilloid receptor antagonist |
GERD |
II |
|
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
|
|
AZD2516 |
metabotropic glutamate receptor 5 antagonist |
GERD |
I |
|
|
NCEs
Phases I and II (continued)
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Neuroscience |
|||||
AZD3480# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
ADHD |
II |
|
|
AZD6765 |
NMDA receptor antagonist |
major depressive disorder |
II |
2013 |
2013 |
AZD2327 |
enkephalinergic receptor modulator |
anxiety and depression |
II |
|
|
AZD2066 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
II |
|
|
AZD8529 |
glutamatergic modulator |
schizophrenia |
II |
|
|
NKTR-118# |
oral peripherally-acting opioid antagonist |
opioid-induced constipation |
II |
2013 |
2013 |
TC-5214# |
nicotinic ion channel blocker |
major depressive disorder |
II |
2014 |
2012 |
TC-5619# |
Alpha7 neuronal nicotinic receptor agonist |
cognitive disorders in schizophrenia |
II |
|
|
AZD7268 |
enkephalinergic receptor modulator |
depression/anxiety |
II |
|
|
AZD1446# |
Alpha4/beta2 neuronal nicotinic receptor agonist |
Alzheimer's disease/ADHD |
II |
|
|
AZD3241 |
myeloperoxidase (MPO) inhibitor |
Parkinson's disease |
I |
|
|
AZD6280 |
GABA receptor subtype partial agonist |
anxiety |
I |
|
|
AZD2516 |
metabotropic glutamate receptor 5 antagonist |
chronic neuropathic pain |
I |
|
|
AZD3043# |
GABA-A receptor modulator |
short acting sedative and anaesthetic |
I |
|
|
AZD8418 |
glutamatergic modulator |
schizophrenia |
I |
|
|
AZD2423 |
chemokine antagonist |
chronic neuropathic pain |
I |
|
|
#Partnered product
NCEs
Phases I and II (continued)
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Oncology & Infection |
|||||
Recentin |
VEGFR tyrosine kinase inhibitor |
NSCLC |
II |
2013 |
2013 |
CytoFab# |
anti-TNF-alpha polyclonal antibody |
severe sepsis |
II |
2014 |
2014 |
AZD6244# (ARRY-142886) |
MEK inhibitor |
solid tumours |
II |
2014 |
2014 |
Olaparib |
PARP inhibitor |
gBRCA breast cancer |
II |
2012 |
2012 |
Olaparib |
PARP inhibitor |
serous ovarian cancer |
II |
2014 |
2014 |
AZD7295 |
NS 5A inhibitor |
hepatitis C |
II |
2015 |
2015 |
AZD1152 |
aurora kinase inhibitor |
haematological malignancies |
II |
2012 |
2012 |
MEDI-3250 |
flu vaccine (quadravalent) |
seasonal influenza |
II |
|
|
CAZ104*# |
beta lactamase inhibitor/cephalosporin |
serious infections |
II |
2012 |
NA |
AZD4769 |
EGFR tyrosine kinase inhibitor |
solid tumours |
I |
|
|
AZD8931 |
erbB kinase inhibitor |
solid tumours |
I |
|
|
AZD7762 |
CHK1 kinase inhibitor |
solid tumours |
I |
|
|
AZD8330# (ARRY-424704) |
MEK inhibitor |
solid tumours |
I |
|
|
CAT-8015 |
recombinant immunotoxin |
haematological malignancies |
I |
|
|
MEDI-534 |
RSV/PIV-3 vaccine |
RSV/PIV prophylaxis |
I |
|
|
MEDI-560 |
PIV-3 vaccine |
intranasal immunisation |
I |
|
|
MEDI-550 |
pandemic influenza virus vaccine |
pandemic influenza vaccine |
I |
|
|
MEDI-557 |
YTE - extended half-life RSV MAb |
RSV prophylaxis |
I |
|
|
AZD8055 |
TOR kinase inhibitor |
range of tumours |
I |
|
|
MEDI-559 |
RSV vaccine |
RSV prophylaxis |
I |
|
|
MEDI-573 |
IGF |
solid tumours |
I |
|
|
MEDI-575 |
PDGFR-alpha |
solid tumours |
I |
|
|
AZD1480 |
JAK2 inhibitor |
myeloproliferative diseases /solid tumours |
I |
|
|
AZD5847 |
Oxazolidinone antibacterial inhibitor |
tuberculosis |
I |
|
|
AZD4547 |
FGFR tyrosine kinase inhibitor |
solid tumours |
I |
|
|
MEDI-547# |
EphA2 conjugate |
solid tumours |
I |
|
|
AZD9742 |
BTGT4 IV |
MRSA |
I |
|
|
CEF104*# |
beta lactamase inhibitor/cephalosporin |
MRSA |
I |
|
NA |
AZD2014 |
MTOR inhibitor |
solid tumours |
I |
|
|
AZD6244 (ARRY-142886) /MK2206# |
MEK/AKT inhibitor |
solid tumours |
I |
|
|
*Subject to review under the Hart Scott Rodino Act
#Partnered product
NCEs
Phases I and II (continued)
Compound |
Mechanism |
Area Under Investigation |
Phase |
Estimated Filing |
|
MAA |
NDA |
||||
Respiratory & Inflammation |
|||||
AZD1981 |
CRTh2 receptor antagonist |
asthma/COPD |
II |
|
|
MEDI-528# |
anti-IL-9 antibody |
asthma |
II |
|
|
CAT-354 |
anti-IL-13 antibody |
asthma |
II |
|
|
AZD9668 |
neutrophil elastase inhibitor |
COPD |
II |
2014 |
2014 |
AZD1236 |
matrix metallo-proteinase inhibitor |
COPD |
II |
|
|
AZD3199 |
iLABA |
asthma/COPD |
II |
|
|
MEDI-563# |
anti-IL-5R antibody |
asthma |
II |
|
|
MEDI-545# |
anti-IFN-alpha antibody |
SLE, myositis |
II |
|
|
AZD9164 |
LAMA |
COPD |
II |
|
|
AZD8848 |
Toll like receptor 7 agonist |
asthma |
II |
|
|
CAM-3001# |
anti-GM-CSFR |
rheumatoid arthritis |
I |
|
|
AZD8566 |
CCR5 |
COPD |
I |
|
|
AZD8075 |
CRTh2 antagonist |
asthma/COPD |
I |
|
|
AZD5985 |
CRTh2 antagonist |
asthma/COPD |
I |
|
|
AZD2551 |
protease inhibitor |
COPD |
I |
|
|
AZD5423 |
iSEGRA |
COPD |
I |
|
|
AZD5122 |
CXCR2 |
COPD |
I |
|
|
AZD8683 |
Muscarinic antagonist |
COPD |
I |
|
|
AZD5069 |
CXCR2 |
COPD |
I |
|
|
MEDI-546# |
anti-IFNaR MAb |
scleroderma |
I |
|
|
#Partnered product
AstraZeneca Development Pipeline
Discontinued Projects vs 30 July 2009 HY
Cardiovascular/Gastrointestinal
NCE/Line Extension |
Compound |
Area Under Investigation |
NCE |
AZD1305 |
arrhythmias |
Neuroscience
NCE/Line Extension |
Compound |
Area Under Investigation |
NCE |
AZD5904 |
multiple sclerosis |
NCE |
AZD6088 |
chronic neuropathic pain |
NCE |
AZD1386 |
chronic neuropathic pain |
NCE |
AZD7325 |
anxiety |
NCE |
AZD4694 |
Alzheimer's disease PET diagnostic |
Oncology & Infection
NCE/Line Extension |
Compound |
Area Under Investigation |
NCE |
AZD9639 |
RSV treatment |
NCE |
CMV Vaccine |
cytomegalovirus |
NCE |
saracatinib |
solid tumours |
NCE |
Zactima |
NSCLC |
Respiratory & Inflammation
NCE/Line Extension |
Compound |
Area Under Investigation |
LCM |
Symbicort pMDI EU |
asthma |
LCM |
Symbicort pMDI EU |
COPD |
Comments
As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.
Compounds in development are displayed by phase.
Key:
MAA - Marketing Authorisation Application (Europe).
NDA - New Drug Application/Biologics Licensing Application (USA).